CompletedNot Applicable

Neonatal Screening of Severe Combined Immunodeficiencies

China180,000 participantsStarted 2015-12

Plain-language summary

The goal of the proposed research is to observe the prevalence and establish the validity of a newborn screening method for severe combined immunodeficiency (SCID). The assay to be used is developed on the basis of PCR quantification of T-cell receptor excision circles (TRECs) that is absent in SCID patients, thus correlating with the disease.

Who can participate

Age range28 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. No more than 28 days old
✓. Newborns who was born in Shanghai and in 2016 to 2020
✓. Blood sample card was collected in 72 hours after birth

Exclusion criteria

✕. Lack of parental consent
✕. Sample card was damaged

What they're measuring

prevalence of SCID

Timeframe: At 28 days after birth

Trial details

NCT IDNCT02590328

SponsorChildren's Hospital of Fudan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12

View on ClinicalTrials.gov More Severe Combined Immunodeficiency trials